InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Dinsmore Christopher, Directeur Scientifique. Officer active across 1 company, notably Kronos Bio, Inc.. In total, 17 filings have been published. Breakdown: 0 buy · 7 sells. Total volume traded: €302k. Activity tracked since 2 August 2021. The latest transaction was filed on 4 January 2024 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations17 total
7,366 shares@ US$1.18361.8% of flowCommon StockSEC:0001209191-24-001067:0
10,032 shares@ US$1.3052.7% of flowCommon StockSEC:0001209191-23-058465:0
6,634 shares@ US$1.75232.3% of flowCommon StockSEC:0001209191-23-041789:0
6,291 shares@ US$1.73552.3% of flowCommon StockSEC:0001209191-23-013017:0
119,882 shares0Common StockSEC:0001209191-23-010603:0
9,138 shares@ US$1.80523.4% of flowCommon StockSEC:0001209191-22-061217:0
43,550 shares0Common StockSEC:0001209191-22-043287:0
43,550 shares0Common StockSEC:0001209191-22-010902:0
43,550 shares0Common StockSEC:0001209191-22-010902
11,212 shares@ US$12.36326.9% of flowCommon StockSEC:0001209191-21-069783
11,212 shares@ US$12.36330.8% of flowCommon StockSEC:0001209191-21-069783:0
9,189 shares@ US$3.276.5% of flowCommon StockSEC:0001209191-21-059138:0
9,189 shares@ US$3.275.7% of flowCommon StockSEC:0001209191-21-059138
9,189 shares@ US$3.276.4% of flowCommon StockSEC:0001209191-21-055252:0
9,189 shares@ US$3.275.6% of flowCommon StockSEC:0001209191-21-055252
9,189 shares@ US$3.276.4% of flowCommon StockSEC:0001209191-21-049401:0
9,189 shares@ US$3.275.6% of flowCommon StockSEC:0001209191-21-049401
17 of 17 declarations
About Dinsmore Christopher
Christopher Dinsmore is the Chief Scientific Officer at Kronos Bio, Inc. He oversees the company's research and development, ensuring innovation and scientific advancement. His expertise is essential for Kronos's success in the biopharmaceutical field.
